KAI (kī) Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of acute cardiovascular disease and kidney disease. KAI’s lead product candidate, KAI-9803, recently completed enrollment in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients undergoing balloon angioplasty. KAI’s second clinical program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, has successfully completed a Phase 1 clinical trial and has demonstrated safety and confirmed its potency and activity via dose-dependent reductions in parathyroid hormone and calcium levels. KAI is currently recruiting a Phase 1b study in patients with end stage renal disease and SHPT.
KAI’s expertise is in the selective modulation of intracellular protein:protein interactions via innovative delivery of peptide drugs into cells which opens up new drug target classes. The Company has applied its core technology to discover highly potent and selective inhibitors and activators for validated members of the protein kinase C (PKC) family of isozymes. This approach has demonstrated therapeutic potential clinically and in many preclinical disease models.
|
|
KAI recently completed enrolling patients in a Phase 2b study of KAI-9803. The Phase 2b trial (PROTECTION AMI) is designed to assess the effect of KAI-9803 on reducing myocardial injury in patients with ST segment elevation myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI). [